Dn B Asset Management As Abb Vie Inc. Transaction History

Dn B Asset Management As

$19.9 Billion
Q2 2024

A detailed history of Dn B Asset Management As transactions in Abb Vie Inc. stock. As of the latest transaction made, Dn B Asset Management As holds 525,526 shares of ABBV stock, worth $91.2 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

525,526

Previous 435,124 20.78%

Holding current value

$91.2 Million

Previous $79.2 Million 13.76%

% of portfolio

0.45%

Previous 0.44%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 05, 2024	BUY	$154.79 - $180.76 $14 Million - $16.3 Million	90,402 Added 20.78%	525,526 $90.1 Million
Q1 2024 Apr 12, 2024	BUY	$159.82 - $182.1 $715,354 - $815,079	4,476 Added 1.04%	435,124 $79.2 Million
Q4 2023 Jan 04, 2024	BUY	$137.6 - $154.97 $1.9 Million - $2.14 Million	13,826 Added 3.32%	430,648 $66.7 Million
Q3 2023 Oct 13, 2023	BUY	$133.59 - $154.65 $3.59 Million - $4.15 Million	26,863 Added 6.89%	416,822 $62.1 Million
Q2 2023 Jul 06, 2023	BUY	$132.51 - $164.9 $5.16 Million - $6.42 Million	38,963 Added 11.1%	389,959 $52.5 Million

Q1 2023 Apr 20, 2023	SELL	$144.61 - $166.54 $6.31 Million - $7.27 Million	-43,641 Reduced 11.06%	350,996 $55.9 Million
Q4 2022 Jan 12, 2023	BUY	$138.31 - $165.87 $1.97 Million - $2.36 Million	14,216 Added 3.74%	394,637 $63.8 Billion
Q3 2022 Oct 11, 2022	SELL	$134.21 - $153.93 $1.98 Million - $2.27 Million	-14,763 Reduced 3.74%	380,421 $51.1 Million
Q2 2022 Jul 08, 2022	SELL	$137.62 - $174.96 $922,329 - $1.17 Million	-6,702 Reduced 1.67%	395,184 $60.5 Billion
Q1 2022 Apr 08, 2022	BUY	$131.98 - $163.75 $1.93 Million - $2.39 Million	14,620 Added 3.78%	401,886 $65.1 Million
Q4 2021 Jan 12, 2022	BUY	$107.43 - $135.93 $1.49 Million - $1.88 Million	13,827 Added 3.7%	387,266 $52.4 Million
Q3 2021 Oct 15, 2021	BUY	$106.4 - $120.78 $5.45 Million - $6.18 Million	51,183 Added 15.88%	373,439 $40.3 Million
Q2 2021 Jul 06, 2021	SELL	$105.21 - $117.21 $7.16 Million - $7.98 Million	-68,098 Reduced 17.45%	322,256 $36.3 Billion
Q1 2021 Apr 15, 2021	BUY	$102.3 - $112.62 $15.5 Million - $17.1 Million	151,696 Added 63.56%	390,354 $42.2 Million
Q4 2020 Jan 19, 2021	SELL	$80.49 - $108.67 $6.9 Million - $9.31 Million	-85,674 Reduced 26.42%	238,658 $25.6 Million
Q3 2020 Oct 14, 2020	SELL	$85.91 - $100.83 $58.1 Million - $68.2 Million	-675,914 Reduced 67.57%	324,332 $28.4 Million
Q2 2020 Jul 08, 2020	BUY	$73.37 - $98.18 $13.5 Million - $18.1 Million	184,022 Added 22.55%	1,000,246 $98.2 Billion
Q1 2020 Apr 17, 2020	BUY	$64.5 - $97.79 $38.7 Million - $58.7 Million	599,999 Added 277.49%	816,224 $62.2 Million
Q4 2019 Jan 13, 2020	BUY	$72.13 - $90.25 $1.94 Million - $2.43 Million	26,876 Added 14.19%	216,225 $19.1 Million
Q3 2019 Oct 16, 2019	BUY	$62.98 - $75.72 $693,850 - $834,207	11,017 Added 6.18%	189,349 $14.3 Million
Q2 2019 Jul 08, 2019	BUY	$65.7 - $83.98 $1.08 Million - $1.38 Million	16,432 Added 10.15%	178,332 $0
Q1 2019 Apr 11, 2019	SELL	$77.14 - $90.79 $1.23 Million - $1.44 Million	-15,901 Reduced 8.94%	161,900 $0
Q4 2018 Jan 15, 2019	SELL	$77.85 - $96.01 $808,394 - $996,967	-10,384 Reduced 5.52%	177,801 $16.4 Million
Q3 2018 Oct 10, 2018	BUY	$88.91 - $98.84 $105,802 - $117,619	1,190 Added 0.64%	188,185 $0
Q2 2018 Jul 06, 2018	BUY	$89.78 - $106.23 $404,010 - $478,035	4,500 Added 2.47%	186,995 $0
Q1 2018 Apr 11, 2018	BUY	$92.01 - $123.21 $1.34 Million - $1.8 Million	14,600 Added 8.7%	182,495 $0
Q4 2017 Jan 10, 2018	BUY	$89.56 - $98.21 $232,856 - $255,345	2,600 Added 1.57%	167,895 $0
Q3 2017 Oct 11, 2017	BUY	$69.85 - $89.22 $11.5 Million - $14.7 Million	165,295	165,295 $0

Others Institutions Holding ABBV

# of Institutions

3,653

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.5M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $307B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.

Account

Dn B Asset Management As Abb Vie Inc. Transaction History